Melanotan II: A Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that researchers have used as a tool to study the melanocortin signaling system. This overview summarizes how the compound is characterized in the scientific literature and where the research currently stands.
What Melanotan II Is
Melanotan II is a lactam-bridged cyclic peptide structurally derived from the active core sequence of alpha-MSH. In published research it is described as a superpotent, broadly acting melanocortin receptor agonist, meaning it engages multiple receptor subtypes within the melanocortin family rather than a single isolated target. Its cyclic structure increases metabolic stability relative to the native hormone, which is one reason researchers have studied it as an experimental probe of melanocortin biology. It is supplied strictly as a research chemical for in-vitro and laboratory study.
Mechanism and What Research Explores
The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R) that participate in pigmentation, energy balance, inflammation, and other physiological signaling pathways. Researchers study MT-II in part because its non-selective agonism lets them examine multiple arms of this system at once. Studies have examined MT-II interaction with MC1R, the receptor most associated with melanin synthesis in melanocytes, as well as central melanocortin receptors that are investigated in the context of appetite and other neuroendocrine signaling. Because the compound activates several receptors, much of the published work focuses on disentangling which observed effects map to which receptor subtype.
Pigmentation Study Areas
Pigmentation is the area where MT-II has been most extensively characterized in the literature. Early controlled investigation, including a pilot phase-I study, documented measurable increases in skin pigmentation following administration, assessed by quantitative reflectance and visual evaluation. Researchers study this melanogenic activity as a model for understanding MC1R-driven melanin production. Importantly, the published literature also documents safety signals: a case report associated MT-II use with cutaneous melanoma in an individual who combined the unlicensed compound with sunbed exposure, underscoring that pigmentation effects come with serious unresolved risk questions. BioRegen does not make or endorse any therapeutic claims about this compound.
Research Stage, Limitations, and Handling Notes
Melanotan II remains an unlicensed, incompletely tested research compound. The published clinical record is limited to small early-phase and observational reports, and the full range of adverse effects is not well characterized. This is an experimental research stage, not an established evidence base, and no regulatory body has approved MT-II for human or veterinary use. Unverified anecdotal reports circulate in online communities; these are unverified anecdotal reports, not controlled findings, and BioRegen does not make or endorse any claims based on them. As a lyophilized peptide, MT-II is generally stored cold and protected from light per standard laboratory peptide handling; for reconstitution practice in a research setting see our guide on how to reconstitute peptides.
Is Melanotan II approved for use?
No. It is an unlicensed research chemical. No compound referenced here is approved for human or veterinary use, and it is supplied for laboratory and educational research only.
Which receptors does Melanotan II act on?
In published research it is described as a broadly acting melanocortin receptor agonist, engaging multiple subtypes including MC1R, which is studied in connection with melanin synthesis.
Why do researchers study it?
Its non-selective melanocortin agonism makes it a useful experimental probe for examining several arms of the melanocortin signaling system, particularly pigmentation pathways.
Exploring the melanocortin pathway for your laboratory work? Start with our research guide, and use code RESEARCH10 for 10% off your first order. You can compare compounds with our research finder or browse related materials in the libido research category.
Selected research references
- Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 1996. https://doi.org/10.1016/0024-3205(96)00160-9
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology, 2013. https://doi.org/10.1159/000356389
Reference metadata sourced via PubMed.
This article is provided for laboratory and educational research purposes only. No compound referenced is approved for human or veterinary use, nothing here constitutes medical advice, and no claim is made that any compound treats, cures, or prevents any condition.